Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy.

Background: Ventricular arrhythmias are a feared complication of arrhythmogenic right ventricular dysplasia/cardiomyopathy. In 2015, an International Task Force Consensus Statement proposed a risk stratification algorithm for implantable cardioverter-defibrillator placement in arrhythmogenic right v...

Descripción completa

Detalles Bibliográficos
Publicado en:Circulation: Arrhythmia & Electrophysiology Vol. 11; no. 2; pp. 1 - 11
Autores principales: Orgeron, Gabriela M., te Riele, Anneline, Tichnell, Crystal, Weijia Wang, Murray, Brittney, Bhonsale, Aditya, Judge, Daniel P., Kamel, Ihab R., Zimmerman, Stephan L., Tandri, Harikrishna, Calkins, Hugh, James, Cynthia A., Wang, Weijia
Formato: research Journal Article
Publicado: Lippincott Williams & Wilkins Feb2018
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=128104740&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 128104740
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        19413149
        6CUA
      jtl: Circulation: Arrhythmia & Electrophysiology
      issn: 19413149
      maglogo: N
    pubinfo:
      dt: Feb2018
      vid: 11
      iid: 2
      pid: 433
      pub: Lippincott Williams & Wilkins
      place: Baltimore, Maryland
    artinfo:
      ui:
        128104740
        128104740
        NLM29453325
        128104740
        10.1161/CIRCEP.117.005593
        NLM29453325
        128104740
      ppf: 1
      ppct: 10
      formats:
      tig:
        atl: Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy.
      aug:
        au:
          Orgeron, Gabriela M.
          te Riele, Anneline
          Tichnell, Crystal
          Weijia Wang
          Murray, Brittney
          Bhonsale, Aditya
          Judge, Daniel P.
          Kamel, Ihab R.
          Zimmerman, Stephan L.
          Tandri, Harikrishna
          Calkins, Hugh
          James, Cynthia A.
          Wang, Weijia
        affil: Department of Medicine, Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD
      sug:
        subj:
          Ventricular Fibrillation Prevention and Control
          Consensus
          Arrhythmogenic Right Ventricular Dysplasia Therapy
          Risk Assessment Methods
          Algorithms
          Defibrillators, Implantable
          Preventive Health Care Standards
          Male
          Prospective Studies
          Adult
          Arrhythmogenic Right Ventricular Dysplasia Complications
          Female
          Data Collection
          Human
          Ventricular Fibrillation Etiology
          Arrhythmogenic Right Ventricular Dysplasia Physiopathology
          Risk Factors
          Ventricular Fibrillation Epidemiology
          United States
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Adult: 19-44 years
          Male
          Female
      ab: Background: Ventricular arrhythmias are a feared complication of arrhythmogenic right ventricular dysplasia/cardiomyopathy. In 2015, an International Task Force Consensus Statement proposed a risk stratification algorithm for implantable cardioverter-defibrillator placement in arrhythmogenic right ventricular dysplasia/cardiomyopathy.Methods and Results: To evaluate performance of the algorithm, 365 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients were classified as having a Class I, IIa, IIb, or III indication per the algorithm at baseline. Survival free from sustained ventricular arrhythmia (VT/VF) in follow-up was the primary outcome. Incidence of ventricular fibrillation/flutter cycle length <240 ms was also assessed. Two hundred twenty-four (61%) patients had a Class I implantable cardioverter-defibrillator indication; 80 (22%), Class IIa; 54 (15%), Class IIb; and 7 (2%), Class III. During a median 4.2 (interquartile range, 1.7-8.4)-year follow-up, 190 (52%) patients had VT/VF and 60 (16%) had ventricular fibrillation/flutter. Although the algorithm appropriately differentiated risk of VT/VF, incidence of VT/VF was underestimated (observed versus expected: 29.6 [95% confidence interval, 25.2-34.0] versus >10%/year Class I; 15.5 [confidence interval 11.1-21.6] versus 1% to 10%/year Class IIa). In addition, the algorithm did not differentiate survival free from ventricular fibrillation/flutter between Class I and IIa patients (P=0.97) or for VT/VF in Class I and IIa primary prevention patients (P=0.22). Adding Holter results (<1000 premature ventricular contractions/24 hours) to International Task Force Consensus classification differentiated risks.Conclusions: While the algorithm differentiates arrhythmic risk well overall, it did not distinguish ventricular fibrillation/flutter risks of patients with Class I and IIa implantable cardioverter-defibrillator indications. Limited differentiation was seen for primary prevention cases. As these are vital uncertainties in clinical decision-making, refinements to the algorithm are suggested prior to implementation.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N